Why cheap aging interventions never get rigorously tested

A paradox haunts longevity medicine: economically viable interventions—fecal microbiota transplantation, senolytic combinations like dasatinib and quercetin, exosome therapies—languish in clinical limbo for decades without rigorous efficacy data on aging, not because they lack promise but because no actor in the system has financial motivation to bankroll the evidence. A defensible clinical trial requires hundreds to thousands of patients and, for interventions that merely slow aging rather than reverse it, at least five years of follow-up to generate meaningful mortality and disease-incidence signals. Regulators and large pharma have inflated trial costs so dramatically that only patentable molecules—those promising monopoly pricing power—attract investor capital; everything else starves. Thirty years of activism to reduce regulatory burden have yielded nothing; FDA approval costs have actually doubled in recent decades. The pragmatic near-term solution, according to longevity researchers, lies in philanthropically funded clinical programs for the most promising affordable interventions, bypassing market incentives entirely and building the evidence base that capital markets will not.